Ticker > Company >

Balaxi Pharma. share price

Balaxi Pharmaceuticals Ltd.

NSE: BALAXI SECTOR: Trading  49.26 K   145   12

46.20
+0.15 (0.33%)
NSE: 17 Sep 03:57 PM

Price Summary

Today's High

₹ 46.68

Today's Low

₹ 45.8

52 Week High

₹ 114.5

52 Week Low

₹ 42.56

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

255.06 Cr.

Enterprise Value

256.75 Cr.

No. of Shares

5.52 Cr.

P/E

105.41

P/B

1.99

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  23.19

CASH

28.69 Cr.

DEBT

30.38 Cr.

Promoter Holding

65.99 %

EPS (TTM)

₹  0.44

Sales Growth

-13.12%

ROE

2.93 %

ROCE

5.12%

Profit Growth

-1.34 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-13.12%
3 Year-15.56%
5 Year5.97%

Profit Growth

1 Year-1.34%
3 Year-37.38%
5 Year-11.13%

ROE%

1 Year2.93%
3 Year9.94%
5 Year20.25%

ROCE %

1 Year5.12%
3 Year13.14%
5 Year26.4%

Debt/Equity

0.2376

Price to Cash Flow

-33.55

Interest Cover Ratio

3.3647

CFO/PAT (5 Yr. Avg.)

0.109746071313266

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 65.99 0.00
Mar 2025 65.99 0.00
Dec 2024 65.99 0.00
Sep 2024 65.99 0.00
Jun 2024 65.99 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 2.733.
  • The company has a high promoter holding of 65.99%.

 Limitations

  • The company has shown a poor profit growth of -37.3811499597176% for the Past 3 years.
  • The company has shown a poor revenue growth of -15.5581446195213% for the Past 3 years.
  • Company has high debtor days of 498.7786.
  • Company has negative cash flow from operations of -7.6023.
  • The company is trading at a high PE of 105.41.
  • The company is trading at a high EV/EBITDA of 39.7938.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 19.03 21.16 11.16 9.65 16.71
Total Expenditure 17.52 19.68 11.06 10.3 16.17
Operating Profit 1.51 1.48 0.1 -0.65 0.54
Other Income 0.85 1.29 2.92 0.32 0.46
Interest 0.35 0.45 0.57 0.69 0.63
Depreciation 0.12 0.12 0.11 0.11 0.11
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.89 2.2 2.33 -1.14 0.26
Tax 0.51 0.54 0.59 0.04 0.06
Profit After Tax 1.38 1.66 1.74 -1.18 0.19
Adjusted EPS (Rs) 0.25 0.3 0.32 -0.21 0.04

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 86.87 101.29 108.14 70.2 60.99
Total Expenditure 67.85 83.99 91.27 64.84 58.38
Operating Profit 19.02 17.3 16.87 5.35 2.61
Other Income 1.81 2.75 6.6 2.4 5.37
Interest 0.15 0.1 0.51 1.66 2.24
Depreciation 0.09 0.25 0.52 0.51 0.46
Exceptional Items 0 0 0 0 0
Profit Before Tax 20.6 19.7 22.45 5.58 5.29
Tax 5.46 5.03 6.23 1.93 1.69
Net Profit 15.13 14.67 16.22 3.65 3.6
Adjusted EPS (Rs.) 3.03 2.93 3.19 0.67 0.65

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 10 10 10.18 10.9 11.04
Total Reserves 33.25 47.91 81.93 110.65 116.81
Borrowings 0 0 0 0 0
Other N/C liabilities 0.01 0.04 2.79 2.78 2.83
Current liabilities 25.67 23.97 34.83 30.04 43.76
Total Liabilities 68.92 81.92 129.72 154.36 174.45
Assets
Net Block 0.69 2.2 7.89 7.1 6.67
Capital WIP 0 0.57 2.83 2.31 22.07
Intangible WIP 0 0 0 0 0
Investments 19.54 19.61 19.54 19.88 25.07
Loans & Advances 0.02 0.59 0.04 1.78 0.62
Other N/C Assets 0 4.87 0.4 0.4 0.4
Current Assets 48.67 54.08 99.02 122.9 119.6
Total Assets 68.92 81.92 129.72 154.36 174.45
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 20.6 19.7 22.45 5.58 5.29
Adjustment 0.1 0.31 0.97 2.05 2.51
Changes in Assets & Liabilities -4.8 -5.44 -25.08 -4.39 -13.77
Tax Paid -2.44 -5.69 -5.41 -5.08 -1.64
Operating Cash Flow 13.46 8.89 -7.07 -1.83 -7.6
Investing Cash Flow -20.03 -6.87 -2.29 0.46 -24.98
Financing Cash Flow 3.49 -1.64 26.39 27.55 17.21
Net Cash Flow -3.08 0.38 17.03 26.19 -15.37

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 65.99 65.99 65.99 65.99 65.99
ashish maheshwari 1.64 1.64 1.64 1.64 1.64
balaxi overseas private l... 63.40 63.40 63.40 63.40 63.40
minoshi maheshwari 0.96 0.96 0.96 0.96 0.96
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 34.01 34.01 34.01 34.01 34.01
amol anand mantri - 1.41 1.41 1.41 1.41
ebisu global opportunitie... - - - 7.73 2.58
investor education and pr... - 0.70 0.70 0.70 0.70
kunal mahendra bhakta 1.86 1.86 1.86 1.86 1.86
multitude growth funds li... - - - - 1.32
nexpact limited - - - - 4.89
p p zibi jose 1.09 1.10 1.12 1.12 1.12
rajasthan global securiti... 2.89 2.89 1.66 2.57 2.57
unico global opportunitie... - - - 8.29 -
elara india opportunities... 8.50 8.29 8.29 - -
mgc fund limited 8.38 8.19 8.19 - -
investor education and pr... 0.70 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2025
Annual Report 2024
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY21
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q2FY21

Company News

Balaxi Pharma. - Quaterly Results 5 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 10 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharmaceuticals’ arm incorporates new wholly owned subsidiary 14 Feb, 5:40 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 3 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 29 May, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 1 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 5 Nov, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 2 Aug, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 23 May, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharma. - Quaterly Results 9 Feb, 12:00 PM Balaxi Pharmaceuticals’ arm completes acquisition of 99% stake in BHES 8 Nov, 4:26 PM Balaxi Pharmaceuticals to expand portfolio of proprietary, niche branded formulations 28 Oct, 11:50 AM Balaxi Pharmaceuticals’ arm acquires 100% stake in Balaxi Healthcare Honduras 12 May, 9:17 AM Balaxi Pharmaceuticals' arm incorporates wholly owned subsidiary 24 Apr, 10:05 AM Balaxi Ventures’ arm acquires BHD, BHG 10 Jun, 2:50 PM

Balaxi Pharma. Stock Price Analysis and Quick Research Report. Is Balaxi Pharma. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Balaxi Pharma.. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Balaxi Pharma. has a PE ratio of 105.407255304586 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Balaxi Pharma. has ROA of 2.1906% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Balaxi Pharma. has a Current ratio of 2.733.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Balaxi Pharma. has a ROE of 2.9324%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Balaxi Pharma. has a Debt to Equity ratio of 0.2376 which means that the company has low proportion of debt in its capital.

  • Sales growth: Balaxi Pharma. has reported revenue growth of -13.1173% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Balaxi Pharma. for the current financial year is 4.27377755041139%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Balaxi Pharma. is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Balaxi Pharma. is Rs 0.4383. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Balaxi Pharma. in Ticker for free. Also, one can get the intrinsic value of Balaxi Pharma. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Balaxi Pharma. FAQs

Q1. What is Balaxi Pharma. share price today?
Ans: The current share price of Balaxi Pharma. is Rs 46.2.

Q2. What is the market capitalisation of Balaxi Pharma.?
Ans: Balaxi Pharma. has a market capitalisation of Rs 255.05865 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Balaxi Pharma.?
Ans: The PE ratio of Balaxi Pharma. is 105.407255304586 and the P/B ratio of Balaxi Pharma. is 1.99192021971484, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Balaxi Pharma. share?
Ans: The 52-week high share price of Balaxi Pharma. is Rs 114.5, and the 52-week low share price of Balaxi Pharma. is Rs 42.56.

Q5. Does Balaxi Pharma. pay dividends?
Ans: Currently, Balaxi Pharma. does not pay dividends. Dividend yield of Balaxi Pharma. is around 0%.

Q6. What are the face value and book value of Balaxi Pharma. shares?
Ans: The face value of Balaxi Pharma. shares is Rs 2, while the book value per share of Balaxi Pharma. is around Rs 23.1937. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Balaxi Pharma.?
Ans: Balaxi Pharma. has a total debt of Rs 30.3797 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Balaxi Pharma.?
Ans: The ROE of Balaxi Pharma. is 2.9324% and ROCE of Balaxi Pharma. is 5.1229%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Balaxi Pharma. a good buy for the long term?
Ans: The Balaxi Pharma. long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Balaxi Pharma. undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Balaxi Pharma. appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Balaxi Pharma.’s financials?
Ans: You can review Balaxi Pharma.’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Balaxi Pharma.
X